Clinical trials: Small Cell Lung Carcinoma Extensive Disease
Small-cell Lung Cancer
Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer
Studies have shown that combining chemotherapy and immune checkpoint inhibitors (ICI) prolongs survival compared with chemotherapy alone in extensive stage small-cell lung cancer (ES SCLC), but the survival benefit is modest.
- Trial name
- TRIPLEX (NCT05223647)
- Testing
- Thoracic radiotherapy, Chemo-immunotherapy
- Where
- 20 sites in Estonia, Iceland and 3 more
- Volunteers
- 239 people
- Sponsor
- Norwegian University of Science and Technology
Small Cell Lung Cancer
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
- Trial name
- NCT01237678
- Testing
- IMGN901, Carboplatin and Etoposide
- Where
- 48 sites in United States, Canada and 2 more
- Volunteers
- 181 people
- Sponsor
- ImmunoGen, Inc.
Small Cell Lung Cancer Extensive Stage
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
Patients with extensive disease SCLC after failure of first-line treatment were enrolled with SHR-1210 and epirubicin for 3 cycles to evaluate initial efficacy
- Trial name
- NCT03755115
- Testing
- Epirubicin plus SHR1210
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer, Lung Cancer
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
RATIONALE: Amifostine may be effective in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy. PURPOSE: This phase II trial is studying how well amifostine works in reducing pain, numbness, tingling…
- Conditions
- Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00078845
- Testing
- Amifostine
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Small Cell Lung Cancer
Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer
This is a phase II trial of abraxane and carboplatin in extensive stage small cell lung cancer to examine overall response rate, time to progressive disease, survival time, and assessment of toxicity profile for Carboplatin and…
- Trial name
- NRR (NCT00454324)
- Testing
- Carboplatin, Abraxane
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Extensive-stage Small-cell Lung Cancer, Liver Metastases
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer…
- Trial name
- BELIEVE (NCT05588388)
- Testing
- Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Kamya Sankar
SCLC,Extensive Stage, Brain Metastases
WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases
This study aims to evaluate the safety and efficacy of hippocampal-sparing WBRT combined with SRS as first-line treatment for SCLC patients with brain metastases.
- Trial name
- NCT06243003
- Testing
- HA-WBRT plus SBRT
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Fudan University
Small Cell Lung Cancer
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
This Phase II study was designed to evaluate the safety and efficacy of albumin paclitaxel in combination with simvastatin compared with treatment with albumin paclitaxel alone in ES-SCLC patients relapsed from first-line…
- Trial name
- NCT04698941
- Testing
- Albumin Paclitaxel, Simvastatin
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Bladder Cancer, Kidney Cancer
Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Bladder Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00016237
- Testing
- tucotuzumab celmoleukin
- Where
- 2 sites in United States
- Sponsor
- EMD Serono
Small Cell Lung Cancer
Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer
Lung cancer is a malignant tumor with high incidence and mortality in China and the world, among which small cell lung cancer (SCLC) accounts for 13% to 17% of lung cancer, and about 250,000 patients are diagnosed with SCLC every…
- Trial name
- NCT06462105
- Testing
- Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
- Volunteers
- 60 people
- Sponsor
- Zhou Chengzhi
Small-cell Lung Cancer, Small Cell Lung Cancer, Combined Type
Molecular Analysis and Treatment Options of SCLC
Small cell lung cancer (SCLC) is an aggressive disease that is characterized by rapid growth and the early development of metastases.
- Conditions
- Small-cell Lung Cancer, Small Cell Lung Cancer, Combined Type, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage
- Trial name
- NCT05945745
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Anlotinib, Durvalumab
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
- Conditions
- Anlotinib, Durvalumab, Small Cell Lung Cancer
- Trial name
- NCT04314297
- Testing
- Anlotinib In Combination With Durvalumab
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Small- Cell Lung Cancer
DC Vaccine Combined With CIK Cells in Patients With SCLC
The aim of this study is to evaluate the safety and efficacy of dendritic cells (DC) combined with cytokine-induced killer (CIK) cells treatment patients with Extensive-Stage Small-Cell Lung Cancer.
- Trial name
- NCT02688673
- Testing
- adenovirus-transfected autologous DC vaccine plus CIK cells
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Small Cell Lung Cancer, Extensive Disease
Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer
Small cell lung cancer is a highly aggressive malignancy. Currently, there is no effective regimen for patients after the progression offirst-line chemotherapy.
- Conditions
- Small Cell Lung Cancer, Extensive Disease, Adoptive Cellular Immunotherapy, Chemotherapy
- Trial name
- NCT03983759
- Testing
- sintilimab maintenance
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
This study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small…
- Conditions
- Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage
- Trial name
- DART-NK-SCLC (NCT07480213)
- Testing
- EB-DART-NK01 (DLL3/CD56 CAR-NK cells), Lymphodepleting chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Immunotherapy, Second-line Treatment
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer
- Trial name
- NCT05901584
- Testing
- Cadonilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University
Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
This is a phase II study evaluating a new combination therapy for untreated extensive-stage small cell lung cancer. The treatment involves an initial phase with the drug Bemotuzumab plus standard chemotherapy and anlotinib…
- Trial name
- NCT07358676
- Testing
- Bemotuzumab + Anlotinib + Chemotherapy + Radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
The purpose of this study is to: Test how well the study medicine Abemaciclib, a CDK4/6 inhibitor, works to shrink lung cancer tumors in the body.
- Conditions
- Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
- Trial name
- NCT04010357
- Testing
- Abemaciclib,
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Case Comprehensive Cancer Center
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
The phase III ASTRUM-005 study (NCT04063163) has demonstrated promising antitumor efficacy and well tolerability of first-line serplulimab combined with chemotherapy in patients with extensive-stage small cell lung cancer…
- Trial name
- NCT06748495
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Hunan Cancer Hospital
Lung Cancer
Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have recurrent or refractory…
- Trial name
- NCT00068289
- Testing
- bortezomib
- Where
- 91 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network